Autoimmune cytopenia in chronic lymphocytic leukemia: Prevalence, clinical associations, and prognostic significance

Blood

Volumn 116, Issue 23, 2010, Pages 4771-4776

  Moreno, Carol ^a   Hodgson, Kate ^a   Ferrer, Gerardo ^a   Elena, Montse ^a   Filella, Xavier ^a   Pereira, Arturo ^a   Baumann, Tycho ^a   Montserrat, Emili ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; CD38 ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; MITOXANTRONE;

ADULT; AGED; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; CONTROLLED STUDY; CYTOPENIA; FEMALE; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTOPENIC PURPURA; TUMOR GROWTH;

EID: 78649747792     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-05-286500     Document Type: Article

References (37)

1. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med. 1995;333(16):1052-1057.
2. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352(8): 804-815.
3. Hamblin TJ. Autoimmune complications of chronic lymphocytic leukemia. Semin Oncol. 2006;33(2):230-239.
4. Mauro FR, Foa R, Cerretti R, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood. 2000;95(9):2786-2792. (Pubitemid 30235886)
5. Zent CS, Ding W, Schwager SM, et al. The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma. Br J Haematol. 2008;141(5):615-621.
6. Dearden C. Disease-specific complications of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2008:450-456.
7. Visco C, Ruggeri M, Laura Evangelista M, et al. Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia. Blood. 2008;111(3):1110-1116.
8. Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46(2):219-234.
9. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48(1):198-206. (Pubitemid 11064396)
10. Moreno C, Montserrat E. New prognostic markers in chronic lymphocytic leukemia. Blood Rev. 2008; 22(4):211-219.
11. Geisler C, Hansen MM. Chronic lymphocytic leukaemia: a test of a proposed new clinical staging system. Scand J Haematol. 1981;27(4):279-286.
12. Cheson BD, Bennett JM, Rai KR, et al. Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group. Am J Hematol. 1988;29(3):152-163.
13. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87(12):4990-4997.
14. Armitage P. Statistical Methods in Medical Research. Malden, MA: Blackwell Science; 2001.
15. Lewis FB, Schwartz RS, Dameshek W. X-radiation and alkylating agents as possible "trigger" mechanisms in the autoimmune complications of malignant lymphoproliferative disease. Clin Exp Immunol. 1966;1(1):3-11.
16. Dameshek W. Chronic lymphocytic leukemia - an accumulative disease of immunologically incompetent lymphocytes. Blood. 1967;29(4):566-584.
17. Galton DA. The pathogenesis of chronic lymphocytic leukemia. Can Med Assoc J. 1966;94(19): 1005-1010.
18. Hall AM, Vickers MA, McLeod E, Barker RN. Rh autoantigen presentation to helper T cells in chronic lymphocytic leukemia by malignant B cells. Blood. 2005;105(5):2007-2015.
19. Beyer M, Kochanek M, Darabi K, et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood. 2005;106(6):2018-2025. (Pubitemid 41291715)
20. Galletti J, Canones C, Morande P, et al. Chronic lymphocytic leukemia cells bind and present the erythrocyte protein band 3: possible role as initiators of autoimmune hemolytic anemia. J Immunol. 2008;181(5):3674-3683.
21. Bowen DA, Call TG, Shanafelt TD, et al. Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone. Leuk Lymphoma. 2010;51(4):620-627.
22. Kaufman M, Rai K. The challenge of treating complex autoimmune cytopenias in chronic lymphocytic leukemia. Leuk Lymphoma. 2010;51(4): 574-575.
23. Bastion Y, Coiffier B, Dumontet C, Espinouse D, Bryon PA. Severe autoimmune hemolytic anemia in two patients treated with fludarabine for chronic lymphocytic leukemia. Ann Oncol. 1992;3(2):171-172.
24. Myint H, Copplestone JA, Orchard J, et al. Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol. 1995;91(2):341-344.
25. Byrd JC, Hertler AA, Weiss RB, et al. Fatal recurrence of autoimmune hemolytic anemia following pentostatin therapy in a patient with a history of fludarabine-associated hemolytic anemia. Ann Oncol. 1995;6(3):300-301.
26. Tertian G, Cartron J, Bayle C, Rudent A, Lambert T, Tchernia G. Fatal intravascular autoimmune hemolytic anemia after fludarabine treatment for chronic lymphocytic leukemia. Hematol Cell Ther. 1996;38(4):359-360.
27. Weiss RB, Freiman J, Kweder SL, Diehl LF, Byrd JC. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia. J Clin Oncol. 1998;16(5):1885-1889.
28. Borthakur G, O'Brien S, Wierda WG, et al. Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab; incidence and predictors. Br J Haematol. 2007;136(6):800-805.
29. Dearden C, Wade R, Else M, et al. The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. Blood. 2008;111(4):1820-1826. (Pubitemid 351451488)
30. Barcellini W, Capalbo S, Agostinelli RM, et al. Relationship between autoimmune phenomena and disease stage and therapy in B-cell chronic lymphocytic leukemia. Haematologica. 2006;91(12): 1689-1692.
31. Vanura K, Le T, Esterbauer H, et al. Autoimmune conditions and chronic infections in chronic lymphocytic leukemia patients at diagnosis are associated with unmutated IgVH genes. Haematologica. 2008;93(12):1912-1916.
32. Ricci F, Tedeschi A, Vismara E, et al. Positive direct antiglobulin test (DAT) in chronic lymphocytic leukemia (CLL) patients: correlation with prognostic factors [abstract]. Blood. 2009;114(22): Abstract 2351.
33. Visco C, Novella E, Peotta E, et al. Autoimmune haemolytic anemia in patients with chronic lymphocytic leukemia is associated with IgVH status. Haematologica. 2010;95(7):1230-1232.
34. Ghia P, Guida G, Stella S, et al. The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood. 2003;101(4): 1262-1269.
35. Zanotti R, Frattini F, Ghia P, et al. ZAP-70 expression is associated with increased risk of autoimmune cytopenias in CLL patients. Am J Hematol. 2010;85(7):494-498.
36. Kyasa MJ, Parrish RS, Schichman SA, Zent CS. Autoimmune cytopenia does not predict poor prognosis in chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Hematol. 2003; 74(1):1-8.
37. Hamblin TJ, Oscier DG, Young BJ. Autoimmunity in chronic lymphocytic leukaemia. J Clin Pathol. 1986;39(7):713-716.